1. Generics Bulletin
  3. >>Generics

FDA Set To Make Key Decision On Restasis Generics

Akorn, Mylan And Teva Are In The Running For ANDA Approvals

 
• By Dean Rudge

Despite the door being opened for generic competition to Restasis more than a year, no FDA approvals for ANDAs referencing the eye-disease drug have been forthcoming. However, that could change before the year is out.

Yes or no decision
Restasis ANDA filers are eyeing an FDA decision by the year end • Source: Shutterstock

Akorn, Mylan and Teva have been tipped to receive “soon” US Food and Drug Administration approvals for the first generics of Allergan’s controversial Restasis (cyclosporine) 0.05% ophthalmic solution, with market entry possible by the end of 2020, Bernstein forecasts.

In 2019, a series of unfavorable legal rulings for the originator – which is now a part of AbbVie –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products